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Abstract 
Atria1 natriuretic peptide (ANP) has become an important parameter for assessing the 
condition of patients with cardiac disease. Recently, attention has also focused on 
N-terminal pro-atria1 natriuretic peptide (NtproANP) in this context. NtproANP circu- 
lates in plasma in higher concentration, is more stable ex vivo, and may be a better 
parameter for cardiac function over time. We have evaluated a new commercially available 
radioimmunoassay kit for NtproANP and compared results and method with those of 
ANP measurements. The NtproANP kit was found to be reliable and easy to use (no 
plasma extraction step is necessary), with good reproducibility (coefficients of variation 
7- 15%). Normal values in 15 healthy laboratory workers, 25 healthy elderly subjects and 
25 patients with heart failure were 207 + 70, 368 + 134 and 1206 f 860 pmol/l, respective- 
ly, 8.3, 11.8 and 13.0 times higher, respectively, than corresponding ANP concentrations. 
NtproANP correlated well with ANP (r 0640.78). We conclude that plasma NtproANP 
measurement may be a good alternative to plasma ANP measurement: technically, it is 
easier tea perform, and NtproANP is more stable in plasma. Whether NtproANP is a better 
diagnostic and prognostic parameter than ANP remains to be further established. 
Keywords: N-Terminal pro-atria] natriuretic peptide; Atria1 natriuretic peptide; Radio- 
immunoassay; Human plasma 
*Corresponding author, Tel.: + 31 10 4633764; Fax: + 31 IO 4634531. 
0098-8981/96/$15.00 0 1996 Elsevier Science B.V. All rights reserved 
PII SOOO9-8981(96)0631 t-5 
42 F. Boomsma et al. I Clinica Chimica Acra 2S2 (19%) 41-49 
1. Introduction 
The measurement in plasma of atria1 natriuretic peptide (ANP), first 
discovered in 1981 [l], has become an important parameter for assessing 
the condition of patients with cardiac disease, and indeed, for identifying 
patients at risk of heart failure [2-51. ANP is a 3-kDa peptide which is 
split off from the C-terminus of a 126-amino acid prohormone mainly 
released from heart atria upon stretching. The remaining 98-amino acid 
fragment, named N-terminal pro-ANP (NtproANP), has no biological 
activity, contrary to ANP itself. Although NtproANP is produced in 
equimolar amounts, it circulates in plasma, due to its much lower 
clearance rate, in much higher concentrations than ANP [6-91. 
NtproANP is also reported to be more stable ex vivo [lO,ll]. In recent 
years, therefore, attention has also focused on measurement of plasma 
NtproANP concentration as an alternative to ANP, especially since 
NtproANP can be determined directly in plasma without the prior 
extraction necessary for ANP measurements. Some reports have con- 
cluded that NtproANP may be a better marker for cardiac dysfunction 
and prognosis than ANP [12-141. 
We have evaluated a radioimmunoassay kit for human plasma 
NtproANP which recently became available commercially and compared 
the NtproANP values measured in plasmas of 15 healthy laboratory 
workers, 25 healthy elderly volunteers and 25 patients with congestive 
heart failure, with ANP values measured in the same samples. 
2. Materials 
2. I. Plasma 
Blood was obtained from subjects and patients who had been in the 
supine position for at least 30 min after insertion of a catheter into an 
antecubital vein. Blood was collected in polystyrene tubes containing 
EDTA and aprotinin (1.9 mg and 100 kIU/ml blood, respectively). The 
tubes were centrifuged within 15 min (4”C, 10 min, 3000 x g) and the 
plasma was separated and stored in polyethylene tubes at -80°C until 
assayed. For some special purposes, blood was collected in heparinized 
tubes with or without glutathione (1.2 mg/ml blood) and in tubes 
containing EDTA (1.9 mg/ml blood) or trisodium citrate (3.4 mg/ml 
blood). 
2.2. NtproANP assay 
NtproANP concentrations in plasma were determined with a commer- 
cial kit from Biotop, Oulu, Finland. This loo-tube kit contains an assay 
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buffer (sodium phosphate), standards (0, 30, 100, 300, 1000 and 3000 
pmol/l), anti-NtproANP produced in rabbits, i2’I-NtproANP (< 1 &i), 
sheep antiserum against rabbit gammaglobulin in polyethylene glycol as a 
precipitation agent, and a control sample. 
2.3. ANP assay 
ANP concentrations in plasma were determined with a commercial kit 
from Nichols Institute, Wijchen, The Netherlands. The procedure and 
characteristics of this method, which involves extraction from plasma 
using C-18 SepPak cartridges followed by radioimmunoassay, have been 
described previously [l&16]. 
2.4 Statistics 
Data are reported as means f S.D., unless otherwise indicated. For 
comparison of paired observations Student’s t-test and Mann-Whitney’s 
U-test were used. P values < 0.05 were considered significant. 
3. Methods 
3. I. Procedure for NtproANP determination 
Into 12 x 75 mm polystyrene tubes were pipetted 25 ~1 standard, 
control or plasma sample followed by 200 ~1 NtproANP antiserum 
(zero-standard and bidistilled water, respectively, for non-specific binding 
determination). After addition of 200 ~1 ‘251-NtproANP, reconstituted in 
assay buffer, the tubes were vortex-mixed and incubated at +4”C for 22 
h. Next, 0.5 ml sheep anti-rabbit gammaglobulin in aqueous polyethylene 
glycol was added (not to the tubes for total counts determination). The 
tubes were mixed, incubated for 30 min at room temperature, and 
centrifuged (15 min, +4”C, 2500 x g). The supernatant was aspirated 
(except for the tubes for total counts determination) and the radioactivity 
was counted for 2 min in a RIASTAR 5420 gamma counter (Packard, 
Meriden, CT). A spline curve-fitting program was used to construct a 
standard curve and determine concentrations of NtproANP in the 
samples. 
4. Results 
The procedure as given by the manufacturer worked well. In 16 
consecutive assays the binding was 35.2 & 3.4% and the non-specific 
binding 1.3 f 0.4%. The ED20, ED50 and ED80 were 1520 f 264, 
419 f 61 and 111 + 16 pmol/l, respectively, while the inflection point was 
at a concentration of 436 & 91 pmol/l. All determinations were carried out 
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in duplicate; average variation between duplicate measurements in a 
typical assay was 3.4 k 3.0%. In all but one of the 16 assays the computer 
program needed only one iteration and no smoothing factor for construct- 
ing the standard curve. A representative standard curve is depicted in 
Fig. 1. 
A control sample provided with the kit (stated to contain 180 pmol/l) 
and a plasma pool (from patients with hypertension and with heart failure) 
were included in all assays at the beginning, in the middle and at the end 
of the assay series. Average interassay values were 194 (CV 9.3%) pmol/l 
for the control and 482 (CV 7.3%) pmol/l for the plasma pool. In 16 assays 
the average values found for the control sample at the beginning, the 
middle and the end of the assay were 179 (CV 6.8%), 197 (CV 14.5%) and 
206 (CV 12.4%) pmol/l, respectively. The corresponding values for the 
plasma pool were 463 (CV 8.2%), 481 (CV 6.8%) and 503 (CV 11.4%) 
pmol/l, respectively. The differences in measured values of both the control 
sample and the plasma pool at the beginning, the middle and the end of 
the assay were statistically significant (repeated measures ANOVA). 
In order to investigate whether plasmas obtained with different an- 
ticoagulation methods give identical results, we measured NtproANP in 
heparinized plasma with and without glutathione, EDTA plasma with and 
00 
NtproANP (pmol/l) 
Fig. 1. Representative standard curve from the NtproANP radioimmunoassay. 
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without aprotinin, and titrated plasma prepared from blood obtained 
from 8 healthy volunteers. EDTA plasma with and without aprotinin gave 
similar results (208 f 81 and 204 f 86 pmol/l, respectively), heparinized 
plasma gave considerably higher NtproANP values, but similar with and 
without glutathione (396 + 119 and 371 f 120 pmol/l, respectively), while 
titrated plasma gave intermediate values (309 + 84 pmol/I). 
The assay is valid in the range 30-3000 pmol/l. The lower limit of 30 
pmol/l is amply sufficient for normal plasmas. In plasmas of patients with 
severe heart failure (NYHA class III/IV) NtproANP concentrations occa- 
sionally exceeded the upper standard level of 3000 pmol/l. In 17 such 
cases, with NtproANP concentrations of 3322 + 212 pmol/l calculated 
from the undiluted samples, the determinations were repeated with lo-fold 
diluted samples. Results were then higher, but not exceedingly so 
(3480 :t 744 pmol/l). 
Plasma NtproANP concentrations found in healthy laboratory 
workers, healthy elderly subjects without overt signs of heart problems 
and in patients with congestive heart failure (age- and sex-matched with 
the healthy elderly subjects) are reported in Table 1. Also reported here 
are the corresponding plasma ANP concentrations and the NtproANP/ 
Table 1 
Data of the three groups of subjects 
Healthy laboratory 
workers 
Healthy elderly 
subjects 
Patients with 
congestive heart 
failure 
n 
Age (years) 
Females./males 
NtproANP (pmol/l) 
Mean k SD. 
Median 
CI 
ANP (pmol/l) 
Mean _t SD. 
Median 
Cl 
NtproANP/ANP ratio 
Mean _t: SD. 
Median 
Cl 
15 25 25 
32 f 8 63 k 4 63 f 3 
817 15jlO 15/10 
207 + 70 
210 
168-245 
26 + 9 
27 
20-31 
8.5 * 2.2 
8.3 
7.3-9.7 
368 f 134 
335 
312-423 
31 f 12 
28 
27-36 
12.2 f 3.6 
11.8 
10.7- 13.7 
1206 f 860 
961 
851-1561 
111 f97 
76 
71-151 
12.1 + 4.9 
13.0 
10.1-14.1 
CI, 95% confidence interval. 
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ANP ratios. Comparison of the two healthy groups showed that 
NtproANP and the NtproANP/ANP ratio were higher in the elderly 
group than in the (younger) laboratory workers, while ANP concentra- 
tions were not significantly different. The heart failure group had higher 
NtproANP and ANP concentrations, while the NtproANP/ANP ratio 
was not different from the ratio of the elderly subjects, but higher than that 
of the laboratory workers. In all three groups NtproANP levels correlated 
strongly with ANP levels (r 0.64-0.69); in the overall group of 65 samples 
the correlation coefficient was 0.78 (Fig. 2),. with a regression line of: 
(pmol/l NtproANP) = 7.5 x (pmol/l ANP) + 195. 
In 8 strongly haemolytic plasmas of subjects without cardiac disease 
normal NtproANP concentrations were found (232 + 41 pmol/l), while 
ANP measurements in these samples were unsuccessful. 
5. Discussion 
The NtproANP kit proved to be a reliable and simple method for 
determining NtproANP levels in plasma, with good reproducibility. A 
slight end-of-assay effect was, however, consistently present. The values 
found in healthy subjects are in agreement with those reported by the 
manufacturer. Mean values reported in the literature, with the use of 
different assay and standardization methods, mostly vary between 160 and 
588 pmol/l [6-8, 12-14, 17-193, but Lerman et al. report a much lower 
A*: . . . . 
. 0 =;ip 
“SO 
Oo 0 
100 
10 100 l( 
Plasma ANP (pmol/l) 
JO 
Fig. 2. Correlation between plasma ANP and plasma NtproANP. 
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value of 28 pmol/l [12]. The values we found in elderly subjects were 
higher than those of younger laboratory workers. This difference suggests 
that NtproANP levels increase with age, as has also been reported by Hall 
et al. [1.4]. As the kidney plays an important role in the metabolism of 
NtproANP [7], it can, however, not be excluded that reduced renal 
function in the elderly is responsible for the higher NtproANP concentra- 
tions. In agreement with previous reports, NtproANP levels in patients 
with congestive heart failure are markedly elevated compared to healthy, 
age- and sex-matched subjects. 
The NtproANP/ANP ratio is not different in the two elderly groups, but 
is lower in the younger group. This is due to the lower NtproANP levels 
in this group, while ANP levels are not different from those in the healthy 
elderly subjects. In the heart failure patients both NtproANP and ANP 
are about 3-fold higher than in the healthy elderly subjects, and thus the 
ratios are not different. Comparison with literature values is fraught with 
difficulties, as ANP levels vary considerably between laboratories and 
assay methods, much more so than NtproANP levels. It is interesting to 
note that Itoh et al. [7] found a ratio of 17.4 in normal controls, but a 
lower ratio of 9.0 in patients with heart failure. 
ANP and NtproANP concentrations were highly correlated, in agree- 
ment with most literature reports [7,9,17,20]. Some authors however 
found a lower correlation coefficient of 0.4-0.5 [13,14] while Lerman et 
al. [12:] found no correlation at all. Release of the atria1 natriuretic 
prohormone leads to equimolar amounts of NtproANP and ANP, but due 
to the much more rapid clearing of ANP from the circulation NtproANP 
circulates in plasma in much higher concentrations. Under stable condi- 
tions a good correlation between NtproANP and ANP concentrations 
might be expected. In situations where ANP levels fluctuate rapidly, 
NtproANP levels remain much more stable [8,13], and in such instances 
the correlation between the two may become less significant. The same 
reasoning may of course explain differences in NtproANP/ANP ratios. 
We conclude that the described kit for plasma NtproANP measurement 
is a reliable method, which offers several advantages compared to mea- 
surement of plasma ANP concentration. Technically, the higher 
NtproANP levels and the lack of necessity for a plasma extraction step 
make the NtproANP measurement easier and less time-consuming to 
perform. In strongly haemolytic blood samples normal NtproANP levels 
were found, while ANP measurements can not be made in such samples. 
Contrary to ANP measurements, measurements of NtproANP rarely fall 
off the standard curve, and if they do, the curve seems to be quite robust 
in this respect. NtproANP is much more stable than ANP, even though 
the latter is not as unstable as has sometimes been suggested [16]; the fact 
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that NtproANP, however, is stable for 3 days at room temperature is a 
great advantage [lO,ll]. From a diagnostic point of view, the much longer 
half-life of NtproANP suggests that it may be a better indicator for heart 
function over time than the short-lived ANP, as has recently been reported 
[13,14]. Only in situations where an indication of rapid changes in heart 
function are of interest would ANP measurement be more advantageous. 
Although from both a practical as well as a theoretical point of view 
measurement of NtproANP seems to be an attractive alternative to 
measurement of ANP, it should first be firmly established that NtproANP 
is at least as good a diagnostic and prognostic parameter as ANP. Further 
studies on the prognostic power of measurements of ANP, NtproANP and 
other neurohormonal parameters on the outcome of cardiac diseases are 
needed therefore before a definitive recommendation for any of these 
parameters can be made. 
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